American College of Cardiology/American Heart Association (ACC/AHA) class I guidelines for the treatment of cholesterol to reduce atherosclerotic cardiovascular risk: Implications for US Hispanics/Latinos based on findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

Waqas T. Qureshi, Robert C. Kaplan, Katrina Swett, Gregory Burke, Martha Daviglus, Molly Jung, Gregory A. Talavera, Diana A. Chirinos, Samantha A. Reina, Sonia Davis, Carlos J. Rodriguez

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background-The prevalence estimates of statin eligibility among Hispanic/Latinos living in the United States under the new 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines are not known. Methods and Results- We estimated prevalence of statin eligibility under 2013 ACC/AHA and 3rd National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP III) guidelines among Hispanic Community Health Study/Study of Latinos (n=16 415; mean age 41 years, 40% males) by using sampling weights calibrated to the 2010 US census. We examined the characteristics of Hispanic/Latinos treated and not treated with statins under both guidelines. We also redetermined the statin-therapy eligibility by using black risk estimates for Dominicans, Cubans, Puerto Ricans, and Central Americans. Compared with NCEP/ATP III guidelines, statin eligibility increased from 15.9% (95% CI 15.0-16.7%) to 26.9% (95% CI 25.7-28.0%) under the 2013 ACC/AHA guidelines. This was mainly driven by the ≥7.5% atherosclerotic cardiovascular disease risk criteria (prevalence 13.9% [95% CI 13.0-14.7%]). Of the participants eligible for statin eligibility under NCEP/ATP III and ACC/AHA guidelines, only 28.2% (95% CI 26.3-30.0%) and 20.6% (95% CI 19.4-21.9%) were taking statins, respectively. Statin-eligible participants who were not taking statins had a higher prevalence of cardiovascular risk factors compared with statin-eligible participants who were taking statins. There was no significant increase in statin eligibility when atherosclerotic cardiovascular disease risk was calculated by using black estimates instead of recommended white estimates (increase by 1.4%, P=0.12) for Hispanic/Latinos. Conclusions- The eligibility of statin therapy increased consistently across all Hispanic/Latinos subgroups under the 2013 ACC/AHA guidelines and therefore will potentially increase the number of undertreated Hispanic/Latinos in the United States.

Original languageEnglish (US)
Article numbere005045
JournalJournal of the American Heart Association
Volume6
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hispanic Americans
Cholesterol
Guidelines
Health
American Heart Association
Cardiology
Therapeutics
Adenosine Triphosphate
Cardiovascular Diseases
Censuses

Keywords

  • ACC/AHA cholesterol treatment
  • Disparities
  • Epidemiology
  • Guideline
  • Hispanics/Latinos
  • Statin therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

American College of Cardiology/American Heart Association (ACC/AHA) class I guidelines for the treatment of cholesterol to reduce atherosclerotic cardiovascular risk : Implications for US Hispanics/Latinos based on findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). / Qureshi, Waqas T.; Kaplan, Robert C.; Swett, Katrina; Burke, Gregory; Daviglus, Martha; Jung, Molly; Talavera, Gregory A.; Chirinos, Diana A.; Reina, Samantha A.; Davis, Sonia; Rodriguez, Carlos J.

In: Journal of the American Heart Association, Vol. 6, No. 5, e005045, 01.05.2017.

Research output: Contribution to journalArticle

@article{f76ee317d18c474ba20d126fbcb42cff,
title = "American College of Cardiology/American Heart Association (ACC/AHA) class I guidelines for the treatment of cholesterol to reduce atherosclerotic cardiovascular risk: Implications for US Hispanics/Latinos based on findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)",
abstract = "Background-The prevalence estimates of statin eligibility among Hispanic/Latinos living in the United States under the new 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines are not known. Methods and Results- We estimated prevalence of statin eligibility under 2013 ACC/AHA and 3rd National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP III) guidelines among Hispanic Community Health Study/Study of Latinos (n=16 415; mean age 41 years, 40{\%} males) by using sampling weights calibrated to the 2010 US census. We examined the characteristics of Hispanic/Latinos treated and not treated with statins under both guidelines. We also redetermined the statin-therapy eligibility by using black risk estimates for Dominicans, Cubans, Puerto Ricans, and Central Americans. Compared with NCEP/ATP III guidelines, statin eligibility increased from 15.9{\%} (95{\%} CI 15.0-16.7{\%}) to 26.9{\%} (95{\%} CI 25.7-28.0{\%}) under the 2013 ACC/AHA guidelines. This was mainly driven by the ≥7.5{\%} atherosclerotic cardiovascular disease risk criteria (prevalence 13.9{\%} [95{\%} CI 13.0-14.7{\%}]). Of the participants eligible for statin eligibility under NCEP/ATP III and ACC/AHA guidelines, only 28.2{\%} (95{\%} CI 26.3-30.0{\%}) and 20.6{\%} (95{\%} CI 19.4-21.9{\%}) were taking statins, respectively. Statin-eligible participants who were not taking statins had a higher prevalence of cardiovascular risk factors compared with statin-eligible participants who were taking statins. There was no significant increase in statin eligibility when atherosclerotic cardiovascular disease risk was calculated by using black estimates instead of recommended white estimates (increase by 1.4{\%}, P=0.12) for Hispanic/Latinos. Conclusions- The eligibility of statin therapy increased consistently across all Hispanic/Latinos subgroups under the 2013 ACC/AHA guidelines and therefore will potentially increase the number of undertreated Hispanic/Latinos in the United States.",
keywords = "ACC/AHA cholesterol treatment, Disparities, Epidemiology, Guideline, Hispanics/Latinos, Statin therapy",
author = "Qureshi, {Waqas T.} and Kaplan, {Robert C.} and Katrina Swett and Gregory Burke and Martha Daviglus and Molly Jung and Talavera, {Gregory A.} and Chirinos, {Diana A.} and Reina, {Samantha A.} and Sonia Davis and Rodriguez, {Carlos J.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1161/JAHA.116.005045",
language = "English (US)",
volume = "6",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - American College of Cardiology/American Heart Association (ACC/AHA) class I guidelines for the treatment of cholesterol to reduce atherosclerotic cardiovascular risk

T2 - Implications for US Hispanics/Latinos based on findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

AU - Qureshi, Waqas T.

AU - Kaplan, Robert C.

AU - Swett, Katrina

AU - Burke, Gregory

AU - Daviglus, Martha

AU - Jung, Molly

AU - Talavera, Gregory A.

AU - Chirinos, Diana A.

AU - Reina, Samantha A.

AU - Davis, Sonia

AU - Rodriguez, Carlos J.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background-The prevalence estimates of statin eligibility among Hispanic/Latinos living in the United States under the new 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines are not known. Methods and Results- We estimated prevalence of statin eligibility under 2013 ACC/AHA and 3rd National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP III) guidelines among Hispanic Community Health Study/Study of Latinos (n=16 415; mean age 41 years, 40% males) by using sampling weights calibrated to the 2010 US census. We examined the characteristics of Hispanic/Latinos treated and not treated with statins under both guidelines. We also redetermined the statin-therapy eligibility by using black risk estimates for Dominicans, Cubans, Puerto Ricans, and Central Americans. Compared with NCEP/ATP III guidelines, statin eligibility increased from 15.9% (95% CI 15.0-16.7%) to 26.9% (95% CI 25.7-28.0%) under the 2013 ACC/AHA guidelines. This was mainly driven by the ≥7.5% atherosclerotic cardiovascular disease risk criteria (prevalence 13.9% [95% CI 13.0-14.7%]). Of the participants eligible for statin eligibility under NCEP/ATP III and ACC/AHA guidelines, only 28.2% (95% CI 26.3-30.0%) and 20.6% (95% CI 19.4-21.9%) were taking statins, respectively. Statin-eligible participants who were not taking statins had a higher prevalence of cardiovascular risk factors compared with statin-eligible participants who were taking statins. There was no significant increase in statin eligibility when atherosclerotic cardiovascular disease risk was calculated by using black estimates instead of recommended white estimates (increase by 1.4%, P=0.12) for Hispanic/Latinos. Conclusions- The eligibility of statin therapy increased consistently across all Hispanic/Latinos subgroups under the 2013 ACC/AHA guidelines and therefore will potentially increase the number of undertreated Hispanic/Latinos in the United States.

AB - Background-The prevalence estimates of statin eligibility among Hispanic/Latinos living in the United States under the new 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines are not known. Methods and Results- We estimated prevalence of statin eligibility under 2013 ACC/AHA and 3rd National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP III) guidelines among Hispanic Community Health Study/Study of Latinos (n=16 415; mean age 41 years, 40% males) by using sampling weights calibrated to the 2010 US census. We examined the characteristics of Hispanic/Latinos treated and not treated with statins under both guidelines. We also redetermined the statin-therapy eligibility by using black risk estimates for Dominicans, Cubans, Puerto Ricans, and Central Americans. Compared with NCEP/ATP III guidelines, statin eligibility increased from 15.9% (95% CI 15.0-16.7%) to 26.9% (95% CI 25.7-28.0%) under the 2013 ACC/AHA guidelines. This was mainly driven by the ≥7.5% atherosclerotic cardiovascular disease risk criteria (prevalence 13.9% [95% CI 13.0-14.7%]). Of the participants eligible for statin eligibility under NCEP/ATP III and ACC/AHA guidelines, only 28.2% (95% CI 26.3-30.0%) and 20.6% (95% CI 19.4-21.9%) were taking statins, respectively. Statin-eligible participants who were not taking statins had a higher prevalence of cardiovascular risk factors compared with statin-eligible participants who were taking statins. There was no significant increase in statin eligibility when atherosclerotic cardiovascular disease risk was calculated by using black estimates instead of recommended white estimates (increase by 1.4%, P=0.12) for Hispanic/Latinos. Conclusions- The eligibility of statin therapy increased consistently across all Hispanic/Latinos subgroups under the 2013 ACC/AHA guidelines and therefore will potentially increase the number of undertreated Hispanic/Latinos in the United States.

KW - ACC/AHA cholesterol treatment

KW - Disparities

KW - Epidemiology

KW - Guideline

KW - Hispanics/Latinos

KW - Statin therapy

UR - http://www.scopus.com/inward/record.url?scp=85019385350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019385350&partnerID=8YFLogxK

U2 - 10.1161/JAHA.116.005045

DO - 10.1161/JAHA.116.005045

M3 - Article

C2 - 28495699

AN - SCOPUS:85019385350

VL - 6

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 5

M1 - e005045

ER -